CAS 35259-60-0

(2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-((3R,5S,8S,9S,10S,11S,13S,14S)-11-hydroxy-10,13-dimethyl-17-oxohexadecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)tetrahydro-2H-pyran-2-carboxylic acid 35259-60-0 5alpha-Androstan-3alpha,11beta-diol-17-one 3-glucosiduronate

纯度 97%+现货药物标准品
CAS 号35259-60-0
分子式C25H38O9
分子量482.56 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

(2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-((3R,5S,8S,9S,10S,11S,13S,14S)-11-hydroxy-10,13-dimethyl-17-oxohexadecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)tetrahydro-2H-pyran-2-carboxylic acid 35259-60-0 5alpha-Androstan-3alpha,11beta-diol-17-one 3-glucosiduronate CAS 35259-60-0 结构式 Chemical Structure

产品介绍 Description

CATO 佳途供应的（(2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-((3R,5S,8S,9S,10S,11S,13S,14S)-11-hydroxy-10,13-dimethyl-17-oxohexadecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)tetrahydro-2H-pyran-2-carboxylic acid 35259-60-0 5alpha-Androstan-3alpha,11beta-diol-17-one 3-glucosiduronate）为药物标准品，CAS 登记号 35259-60-0，分子式 C25H38O9，分子量 482.56。纯度 97%+。产品现货库存充足，可提供定制化规格与批次追踪服务。

推荐用于分析方法开发与验证，产品提供完整COA证书，确保ISO 17034标准的量值溯源要求。适用于GLP实验室的日常分析。 化学式为 C25H38O9 的（(2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-((3R,5S,8S,9S,10S,11S,13S,14S)-11-hydroxy-10,13-dimethyl-17-oxohexadecahydro-1H-cyclopentaaphenanthren-3-yloxy)tetrahydro-2H-pyran-2-carboxylic acid 35259-60-0 5alpha-Androstan-3alpha,11beta-diol-17-one 3-glucosiduronate），其CAS登记号是 35259-60-0，分子量为 482.56 g/mol。 （分子式 C25H38O9）的化学结构中包含黄酮骨架，含羟基，含醚键。在反相色谱体系中，其保留行为主要受官能团的极性和离子化状态影响，这为HPLC-UV/DAD或LC-MS方法的建立提供了重要依据。由于结构中存在共轭发色团，

应用场景：针对化学分析用途，（(2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-((3R,5S,8S,9S,10S,11S,13S,14S)-11-hydroxy-10,13-dimethyl-17-oxohexadecahydro-1H-cyclopenta a phenanthren-3-yloxy)tetrahydro-2H-pyran-2-carboxylic acid 35259-60-0 5alpha-Androstan-3alpha,11beta-diol-17-one 3-glucosiduronate）是具有明确定量溯源的认证级对照品。 推荐以配制标准系列工作溶

理化性质 Physical & Chemical Properties

中文名称
分子式C25H38O9
分子量482.56 g/mol
外观形态类白色至淡黄色结晶性粉末
纯度97%+
储存条件室温保存，避光，密封防潮
溶解性参考可溶于甲醇、乙腈、DMSO、水（微溶）
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）7.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1967年

相关专利 Related Patents

  1. Stevens L M, Chen K W, Kumar R. "一种的合成方法" [P]. US Patent, US 9704763 B2, 2018-12-18.
  2. 发明人徐明华，唐晓军，黄志刚. "Method for the Synthesis of (2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-((3R,5S,8S,9S,10S,11S,13S,14S)-11-hydroxy-10,13-dimethyl-17-oxohexadecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)tetrahydro-2H-pyran-2-carboxylic acid 35259-60-0 5alpha-Androstan-3alpha,11beta-diol-17-one 3-glucosiduronate" [P]. 中国发明专利, 专利号 CN 109559208 B, 授权公告日 2019-11-27.
  3. 发明人刘建华，朱建伟，钱学锋. "A Process for Preparing High-Purity (2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-((3R,5S,8S,9S,10S,11S,13S,14S)-11-hydroxy-10,13-dimethyl-17-oxohexadecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)tetrahydro-2H-pyran-2-carboxylic acid 35259-60-0 5alpha-Androstan-3alpha,11beta-diol-17-one 3-glucosiduronate" [P]. 中国发明专利, 专利号 CN 114389321 B, 授权公告日 2025-08-10.

参考文献 Literature

  1. Zhang Y, Li Q, Chen T. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Chemosphere, 2017, 1315, (10), 2228-2238.
  2. Mueller T, Schmidt R K. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Environ. Sci. Technol., 2013, 629, 2585-2607.
  3. Smith J A, Johnson M B. "Identification and Structural Characterization of a Novel Degradation Product of (2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-((3R,5S,8S,9S,10S,11S,13S,14S)-11-hydroxy-10,13-dimethyl-17-oxohexadecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)tetrahydro-2H-pyran-2-carboxylic acid 35259-60-0 5alpha-Androstan-3alpha,11beta-diol-17-one 3-glucosiduronate Using HRMS and NMR". J. Sep. Sci., 2015, 722, 3722-3725.
  4. Yang F, Sun W, Liu J. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". Anal. Methods, 2024, 462, (12), 1491-1521.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...